Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence.
Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.
Written by:
Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA. Are you the author?
Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M59, Baltimore, MD 21287, USA.
Reference: Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19.
doi: 10.1016/j.hoc.2013.08.005
PubMed Abstract
PMID: 24188259
UroToday.com Prostate Cancer Section
